JP2003524621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524621A5 JP2003524621A5 JP2000609543A JP2000609543A JP2003524621A5 JP 2003524621 A5 JP2003524621 A5 JP 2003524621A5 JP 2000609543 A JP2000609543 A JP 2000609543A JP 2000609543 A JP2000609543 A JP 2000609543A JP 2003524621 A5 JP2003524621 A5 JP 2003524621A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- host
- cntf
- cell
- recipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 19
- 239000003102 growth factor Substances 0.000 description 15
- 230000002207 retinal effect Effects 0.000 description 12
- 239000003124 biologic agent Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000004240 ciliary body Anatomy 0.000 description 7
- 230000003412 degenerative effect Effects 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 208000002177 Cataract Diseases 0.000 description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 description 6
- 208000010412 Glaucoma Diseases 0.000 description 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 6
- 201000000582 Retinoblastoma Diseases 0.000 description 6
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 208000002780 macular degeneration Diseases 0.000 description 6
- 208000032253 retinal ischemia Diseases 0.000 description 6
- 230000001228 trophic effect Effects 0.000 description 6
- 239000003181 biological factor Substances 0.000 description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- -1 IL-1β Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 description 4
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 229940097998 neurotrophin 4 Drugs 0.000 description 4
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008354 tissue degradation Effects 0.000 description 4
- 102100026376 Artemin Human genes 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 101000785776 Homo sapiens Artemin Proteins 0.000 description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010092801 Midkine Proteins 0.000 description 3
- 102000016776 Midkine Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12792699P | 1999-04-06 | 1999-04-06 | |
| US60/127,926 | 1999-04-06 | ||
| US09/543,119 | 2000-04-05 | ||
| US09/543,119 US6361771B1 (en) | 1999-04-06 | 2000-04-05 | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| PCT/US2000/009150 WO2000060051A2 (en) | 1999-04-06 | 2000-04-06 | Arpe-19 as a platform cell line for encapsulated cell-based delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010256357A Division JP2011074079A (ja) | 1999-04-06 | 2010-11-16 | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003524621A JP2003524621A (ja) | 2003-08-19 |
| JP2003524621A5 true JP2003524621A5 (enExample) | 2011-01-13 |
| JP4954374B2 JP4954374B2 (ja) | 2012-06-13 |
Family
ID=26826092
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609543A Expired - Lifetime JP4954374B2 (ja) | 1999-04-06 | 2000-04-06 | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
| JP2010256357A Withdrawn JP2011074079A (ja) | 1999-04-06 | 2010-11-16 | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010256357A Withdrawn JP2011074079A (ja) | 1999-04-06 | 2010-11-16 | カプセル化された細胞ベースの送達のためのプラットホーム細胞株としてのａｒｐｅ−１９ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6361771B1 (enExample) |
| EP (1) | EP1171573B1 (enExample) |
| JP (2) | JP4954374B2 (enExample) |
| AT (1) | ATE269715T1 (enExample) |
| AU (1) | AU773387B2 (enExample) |
| BR (1) | BR0009562A (enExample) |
| CA (1) | CA2365532C (enExample) |
| DE (1) | DE60011761T2 (enExample) |
| DK (1) | DK1171573T3 (enExample) |
| ES (1) | ES2219335T3 (enExample) |
| NO (1) | NO20014856D0 (enExample) |
| WO (1) | WO2000060051A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| US20070071734A1 (en) * | 1999-04-06 | 2007-03-29 | Weng Tao | ARPE-19 as platform cell line for encapsulated cell-based delivery |
| US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| WO2003033016A1 (en) * | 2001-10-16 | 2003-04-24 | Jenny Phipps | Use of neurotrophic factors for treating neurodegenerative diseases and cancer |
| EP1501541A1 (en) * | 2002-04-30 | 2005-02-02 | Canadian Blood Services | Encapsulated cells to elicit immune responses |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| EP1897552B1 (en) | 2003-04-18 | 2009-06-17 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
| AU2004245175C1 (en) * | 2003-06-10 | 2010-03-18 | Biogen Ma Inc. | Improved secretion of neublastin |
| US7927599B2 (en) | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
| US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
| US8257963B2 (en) | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
| US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
| AU2004283053A1 (en) | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of Parkinson's Disease |
| AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
| DK1786454T3 (da) * | 2004-08-19 | 2010-09-06 | Biogen Idec Inc | Neublastinvarianter |
| CN101043899B (zh) | 2004-08-19 | 2011-03-30 | 比奥根艾迪克Ma公司 | 重折叠转化型生长因子beta家族蛋白 |
| US8088567B2 (en) * | 2005-04-01 | 2012-01-03 | Nsgene A/S | Human immortalised neural precursor cell line |
| WO2006122551A2 (en) * | 2005-05-17 | 2006-11-23 | Nsgene A/S | An implantable therapy system for treating a living being with an active factor |
| WO2007042040A2 (en) * | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
| AU2006308312A1 (en) * | 2005-10-28 | 2007-05-03 | Nsgene A/S | Implantable Biocompatible Immunoisolatory Vehicle for Delivery of GDNF |
| EP1971288B1 (en) * | 2005-12-30 | 2013-02-13 | Neurotech USA, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
| TWI445544B (zh) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
| US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
| US8075537B2 (en) * | 2008-08-15 | 2011-12-13 | Oxyband Technologies, Inc. | Multiple cell therapeutic diffusion device |
| CA2750027C (en) | 2009-01-23 | 2020-11-10 | Nsgene A/S | Improved cell lines and their use in encapsulated cell biodelivery |
| WO2010083842A2 (en) | 2009-01-23 | 2010-07-29 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
| US20150024024A1 (en) * | 2009-04-23 | 2015-01-22 | Neurotech Usa, Inc. | Cell Lines That Produce Prostaglandin F2 Alpha (PGF2A) And Uses Thereof |
| EP2486128A4 (en) * | 2009-10-08 | 2013-10-09 | Neurotech Usa Inc | USE OF THE PEDF IN AN ENCAPSULATED CELL DELIVERY SYSTEM |
| US20110104154A1 (en) * | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
| AU2011279250B2 (en) | 2010-07-12 | 2014-12-04 | California Institute Of Technology | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
| EP2646007B1 (en) * | 2010-12-02 | 2016-12-21 | Neurotech USA, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
| US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
| WO2012149468A2 (en) | 2011-04-29 | 2012-11-01 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
| CN110777124A (zh) | 2011-10-27 | 2020-02-11 | 威尔斯达眼科制剂公司 | 编码视杆细胞来源的视锥细胞活力因子的载体 |
| US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
| JP2015519370A (ja) | 2012-05-30 | 2015-07-09 | ニューロテック ユーエスエー， インコーポレイテッド | 低温保存される植込み型細胞培養デバイスおよびその使用 |
| WO2014200997A2 (en) * | 2013-06-10 | 2014-12-18 | Millennium Pharmaceuticals, Inc. | Method for preparing three-dimensional, organotypic cell cultures and uses thereof |
| EP3043836B1 (en) * | 2013-09-11 | 2023-05-10 | Neurotech USA, Inc. | Encapsulated cell therapy cartridge |
| FR3014316B1 (fr) * | 2013-12-10 | 2017-01-20 | Defymed | Organe bioartificiel |
| US20170266354A1 (en) | 2014-09-04 | 2017-09-21 | Kemijski Institut | Cell-Based Device For Local Treatment With Therapeutic Protein |
| JP6850734B2 (ja) * | 2015-05-27 | 2021-03-31 | ニューロテック ユーエスエー， インコーポレイテッド | 眼の障害の処置のためのカプセル化細胞療法の使用 |
| WO2019169333A1 (en) | 2018-03-02 | 2019-09-06 | Sigilon Therapeutics, Inc. | Afibrotic compounds, devices, and uses thereof |
| EP3759154A1 (en) | 2018-03-02 | 2021-01-06 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| CN112203646A (zh) | 2018-04-04 | 2021-01-08 | 西吉隆医疗股份有限公司 | 可植入颗粒和相关方法 |
| US12649930B2 (en) | 2019-03-27 | 2026-06-09 | Sigilon Therapeutics, Inc. | Compositions, devices, and methods for treating Fabry disease |
| US12697300B2 (en) | 2019-08-08 | 2026-08-04 | William Marsh Rice University | Implantable constructs and uses thereof |
| WO2021087476A1 (en) | 2019-11-01 | 2021-05-06 | Neurotech Usa, Inc. | System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device |
| US20230047254A1 (en) * | 2019-12-29 | 2023-02-16 | Gloriana Therapeutics | Mammalian Cells Secreting GDNF and Their Therapeutic Use |
| EP4103237A4 (en) * | 2020-02-11 | 2024-03-20 | William Marsh Rice University | METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS |
| EP4120958B1 (en) | 2020-03-18 | 2026-04-29 | Takeda Pharmaceutical Company Limited | Implantable cell chamber device and uses thereof |
| JP2023521400A (ja) | 2020-04-09 | 2023-05-24 | デファイメッド | 医療デバイス用の膜 |
| EP3892259A1 (en) | 2020-04-09 | 2021-10-13 | Defymed | Membranes for medical devices |
| WO2022011081A1 (en) | 2020-07-09 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cell lines that produce human retinoschisin proteins and uses thereof |
| JP2024518433A (ja) | 2021-05-06 | 2024-05-01 | ホバ セラピューティクス エーピーエス | 化学療法誘発性神経障害性疼痛の予防及び治療 |
| JP7523622B2 (ja) * | 2021-10-28 | 2024-07-26 | ヴィアサイト インコーポレイテッド | 埋め込み可能な封入デバイスと共に使用するツールおよび器具 |
| KR20240118796A (ko) | 2021-12-10 | 2024-08-05 | 호바 세라퓨틱스 에이피에스 | 침해수용성 통증의 치료 |
| CN121285568A (zh) | 2023-03-30 | 2026-01-06 | 制药五有限责任公司 | 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体 |
| WO2026072752A1 (en) | 2024-09-27 | 2026-04-02 | Pharma Cinq, Llc | Rod-derived cone viability factor fusion protein |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| FR2681609B1 (fr) | 1991-09-24 | 1994-12-30 | Centre Nat Rech Scient | Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale. |
| AU684050B2 (en) | 1992-07-13 | 1997-12-04 | Baylor College Of Medicine | Targeting somatic gene therapy to joints |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| AU688776B2 (en) | 1993-06-23 | 1998-03-19 | Brown University Research Foundation | Method and apparatus for sealing implantable, membrane encapsulation devices |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6020192A (en) * | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
| US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
| US5998598A (en) * | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
| US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
| US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
-
2000
- 2000-04-05 US US09/543,119 patent/US6361771B1/en not_active Expired - Lifetime
- 2000-04-06 AT AT00923144T patent/ATE269715T1/de active
- 2000-04-06 DK DK00923144T patent/DK1171573T3/da active
- 2000-04-06 CA CA2365532A patent/CA2365532C/en not_active Expired - Lifetime
- 2000-04-06 JP JP2000609543A patent/JP4954374B2/ja not_active Expired - Lifetime
- 2000-04-06 EP EP00923144A patent/EP1171573B1/en not_active Expired - Lifetime
- 2000-04-06 AU AU43319/00A patent/AU773387B2/en not_active Expired
- 2000-04-06 ES ES00923144T patent/ES2219335T3/es not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009150 patent/WO2000060051A2/en not_active Ceased
- 2000-04-06 US US09/958,040 patent/US7115257B1/en not_active Expired - Lifetime
- 2000-04-06 BR BRPI0009562-1A patent/BR0009562A/pt not_active IP Right Cessation
- 2000-04-06 DE DE60011761T patent/DE60011761T2/de not_active Expired - Lifetime
-
2001
- 2001-10-05 NO NO20014856A patent/NO20014856D0/no not_active Application Discontinuation
-
2010
- 2010-11-16 JP JP2010256357A patent/JP2011074079A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12605156B2 (en) | Tissue clamp and implantation method | |
| EP3666236B1 (en) | Glaucoma implant device | |
| EP1574209B1 (en) | Method for treating ophthalmic diseases | |
| Friedberg et al. | A new technique for repositioning and fixating a dislocated intraocular lens | |
| US20030031700A1 (en) | Device and method for treating ophthalmic diseases | |
| KR20020059630A (ko) | 약물 전달 장치 | |
| MXPA05000807A (es) | Dispositivo de drenaje uveoescleral. | |
| CA2365532A1 (en) | Arpe-19 as a platform cell line for encapsulated cell-based delivery | |
| US8573961B2 (en) | Mold for manufacturing a foldable artificial vitreous body | |
| CN105125341B (zh) | 一种用于眼科手术的手术装置 | |
| US10278920B1 (en) | Drug delivery implant and a method using the same | |
| Tanito et al. | Tube insertion of Ahmed glaucoma valve using a Micro-incision scleral tunnel technique | |
| Gaudric et al. | Use of autologous platelet concentrate in macular hole surgery: report of 77 cases | |
| CN120022134A (zh) | 角膜扩张性疾病治疗的个性化角膜接触镜微针装置 | |
| Yassur et al. | Laser iridotomy in closed-angle glaucoma | |
| RU2079295C1 (ru) | Способ имплантации опорного элемента при проведении первого этапа кератопротезирования | |
| RU2251396C2 (ru) | Способ лечения осложнения после лазерного кератомилеза | |
| Levy et al. | Clinical experience with Nd: YAG laser vitreolysis in the anterior segment | |
| RU2090166C1 (ru) | Способ лечения десцеметоцеле | |
| Nielsen et al. | The effect of indomethacin 1% ophthalmic suspension in preventing surgically induced miosis at extracapsular cataract surgery | |
| Gekeler et al. | Implantation and explantation of active subretinal visual prostheses using a combined transcutaneous and transchoroidal approach | |
| Avni et al. | Epikeratophakia after ocular trauma | |
| RU2334495C1 (ru) | Способ лечения субретинальной неоваскуляризации | |
| McCool et al. | Intracapsular extraction of senile cataract | |
| RU2164124C1 (ru) | Способ профилактики металлоза при вколоченных инородных телах заднего полюса глазного яблока |